bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung

Reuters

07-22

bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung

bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath® Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled "System and Method for Determining Lung Health," safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath® Lung and expands its global intellectual property portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722210397) on July 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553256691"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553256691\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553256691?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553256691","market":"nz","top_or_hot":-1,"title":"bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath® Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled \"System and Method for Determining Lung Health,\" safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath® Lung and expands its global intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722210397) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nbioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath® Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled \"System and Method for Determining Lung Health,\" safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath® Lung and expands its global intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722210397) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIAF","symbol_name":"bioAffinity Technologies, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL7jrgzn:1","article_id":"2553256691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553256691","pubTimestamp":1753189262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled \"System and Method for Determining Lung Health,\" safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath Lung and expands its global intellectual property portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIAF":"bioAffinity Technologies, Inc.","BK4139":"生物科技"},"translate_title":"bioAffinity Technologies获得创新肺癌诊断测试CyPath的加拿大专利®肺","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":0.9},"content_text":"bioAffinity Technologies Secures Canadian Patent for Innovative Lung Cancer Diagnostic Test, CyPath® Lung\n    \n\n        bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath® Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled \"System and Method for Determining Lung Health,\" safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath® Lung and expands its global intellectual property portfolio.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722210397) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}